ID   RNF31_HUMAN             Reviewed;        1072 AA.
AC   Q96EP0; A0A962; Q86VI2; Q8TEI0; Q96GB4; Q96NF1; Q9H5F1; Q9NWD2;
DT   15-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   28-JUN-2023, entry version 202.
DE   RecName: Full=E3 ubiquitin-protein ligase RNF31;
DE            EC=2.3.2.31 {ECO:0000269|PubMed:17006537, ECO:0000269|PubMed:19136968, ECO:0000269|PubMed:20005846, ECO:0000269|PubMed:28481331};
DE   AltName: Full=HOIL-1-interacting protein {ECO:0000303|PubMed:22863777};
DE            Short=HOIP {ECO:0000303|PubMed:22863777};
DE   AltName: Full=RING finger protein 31 {ECO:0000312|HGNC:HGNC:16031};
DE   AltName: Full=RING-type E3 ubiquitin transferase RNF31 {ECO:0000305};
DE   AltName: Full=Zinc in-between-RING-finger ubiquitin-associated domain protein {ECO:0000303|PubMed:15093743};
GN   Name=RNF31 {ECO:0000312|HGNC:HGNC:16031};
GN   Synonyms=ZIBRA {ECO:0000303|PubMed:15093743};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), ALTERNATIVE SPLICING, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=15093743; DOI=10.1016/j.yexcr.2004.01.019;
RA   Thompson H.G.R., Harris J.W., Lin L., Brody J.P.;
RT   "Identification of the protein Zibra, its genomic organization, regulation,
RT   and expression in breast cancer cells.";
RL   Exp. Cell Res. 295:448-459(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), IDENTIFICATION IN THE LUBAC
RP   COMPLEX, FUNCTION OF THE LUBAC COMPLEX, CATALYTIC ACTIVITY, PATHWAY, AND
RP   MUTAGENESIS OF CYS-699; CYS-702; CYS-871 AND CYS-874.
RX   PubMed=17006537; DOI=10.1038/sj.emboj.7601360;
RA   Kirisako T., Kamei K., Murata S., Kato M., Fukumoto H., Kanie M., Sano S.,
RA   Tokunaga F., Tanaka K., Iwai K.;
RT   "A ubiquitin ligase complex assembles linear polyubiquitin chains.";
RL   EMBO J. 25:4877-4887(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ILE-1061.
RC   TISSUE=Embryo, and Hair follicle dermal papilla;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 526-1072 (ISOFORMS 1/3).
RC   TISSUE=Spleen;
RX   PubMed=12693554; DOI=10.1093/dnares/10.1.49;
RA   Jikuya H., Takano J., Kikuno R., Hirosawa M., Nagase T., Nomura N.,
RA   Ohara O.;
RT   "Characterization of long cDNA clones from human adult spleen. II. The
RT   complete sequences of 81 cDNA clones.";
RL   DNA Res. 10:49-57(2003).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-466, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-466, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   POLYUBIQUITIN-BINDING, FUNCTION OF THE LUBAC COMPLEX, CATALYTIC ACTIVITY,
RP   PATHWAY, ASSOCIATION WITH TNF-RSC, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=20005846; DOI=10.1016/j.molcel.2009.10.013;
RA   Haas T.L., Emmerich C.H., Gerlach B., Schmukle A.C., Cordier S.M.,
RA   Rieser E., Feltham R., Vince J., Warnken U., Wenger T., Koschny R.,
RA   Komander D., Silke J., Walczak H.;
RT   "Recruitment of the linear ubiquitin chain assembly complex stabilizes the
RT   TNF-R1 signaling complex and is required for TNF-mediated gene induction.";
RL   Mol. Cell 36:831-844(2009).
RN   [11]
RP   FUNCTION OF THE LUBAC COMPLEX, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=19136968; DOI=10.1038/ncb1821;
RA   Tokunaga F., Sakata S., Saeki Y., Satomi Y., Kirisako T., Kamei K.,
RA   Nakagawa T., Kato M., Murata S., Yamaoka S., Yamamoto M., Akira S.,
RA   Takao T., Tanaka K., Iwai K.;
RT   "Involvement of linear polyubiquitylation of NEMO in NF-kappaB
RT   activation.";
RL   Nat. Cell Biol. 11:123-132(2009).
RN   [12]
RP   IDENTIFICATION IN THE LUBAC COMPLEX, AND FUNCTION.
RX   PubMed=21455173; DOI=10.1038/nature09816;
RA   Gerlach B., Cordier S.M., Schmukle A.C., Emmerich C.H., Rieser E.,
RA   Haas T.L., Webb A.I., Rickard J.A., Anderton H., Wong W.W., Nachbur U.,
RA   Gangoda L., Warnken U., Purcell A.W., Silke J., Walczak H.;
RT   "Linear ubiquitination prevents inflammation and regulates immune
RT   signalling.";
RL   Nature 471:591-596(2011).
RN   [13]
RP   IDENTIFICATION IN THE LUBAC COMPLEX, AND FUNCTION.
RX   PubMed=21455180; DOI=10.1038/nature09815;
RA   Tokunaga F., Nakagawa T., Nakahara M., Saeki Y., Taniguchi M., Sakata S.,
RA   Tanaka K., Nakano H., Iwai K.;
RT   "SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain
RT   assembly complex.";
RL   Nature 471:633-636(2011).
RN   [14]
RP   IDENTIFICATION IN THE LUBAC COMPLEX, FUNCTION, DOMAIN RANBP2-TYPE,
RP   UBIQUITIN-BINDING, AND MUTAGENESIS OF CYS-699; CYS-702; CYS-871 AND
RP   CYS-874.
RX   PubMed=21455181; DOI=10.1038/nature09814;
RA   Ikeda F., Deribe Y.L., Skanland S.S., Stieglitz B., Grabbe C.,
RA   Franz-Wachtel M., van Wijk S.J., Goswami P., Nagy V., Terzic J.,
RA   Tokunaga F., Androulidaki A., Nakagawa T., Pasparakis M., Iwai K.,
RA   Sundberg J.P., Schaefer L., Rittinger K., Macek B., Dikic I.;
RT   "SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB
RT   activity and apoptosis.";
RL   Nature 471:637-641(2011).
RN   [15]
RP   FUNCTION, DOMAIN RING, DOMAIN LDD, AND ENZYME MECHANISM.
RX   PubMed=22863777; DOI=10.1038/emboj.2012.217;
RA   Smit J.J., Monteferrario D., Noordermeer S.M., van Dijk W.J.,
RA   van der Reijden B.A., Sixma T.K.;
RT   "The E3 ligase HOIP specifies linear ubiquitin chain assembly through its
RT   RING-IBR-RING domain and the unique LDD extension.";
RL   EMBO J. 31:3833-3844(2012).
RN   [16]
RP   INTERACTION WITH RBCK1/HOIL1.
RX   PubMed=22430200; DOI=10.1038/embor.2012.24;
RA   Yagi H., Ishimoto K., Hiromoto T., Fujita H., Mizushima T., Uekusa Y.,
RA   Yagi-Utsumi M., Kurimoto E., Noda M., Uchiyama S., Tokunaga F., Iwai K.,
RA   Kato K.;
RT   "A non-canonical UBA-UBL interaction forms the linear-ubiquitin-chain
RT   assembly complex.";
RL   EMBO Rep. 13:462-468(2012).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-383 AND SER-466, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH OTULIN.
RX   PubMed=23708998; DOI=10.1038/nature12296;
RA   Rivkin E., Almeida S.M., Ceccarelli D.F., Juang Y.C., Maclean T.A.,
RA   Srikumar T., Huang H., Dunham W.H., Fukumura R., Xie G., Gondo Y.,
RA   Raught B., Gingras A.C., Sicheri F., Cordes S.P.;
RT   "The linear ubiquitin-specific deubiquitinase gumby regulates
RT   angiogenesis.";
RL   Nature 498:318-324(2013).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-383 AND SER-466, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   FUNCTION, INTERACTION WITH SPATA2, AND MUTAGENESIS OF ASN-102.
RX   PubMed=27458237; DOI=10.15252/embr.201642592;
RA   Schlicher L., Wissler M., Preiss F., Brauns-Schubert P., Jakob C.,
RA   Dumit V., Borner C., Dengjel J., Maurer U.;
RT   "SPATA2 promotes CYLD activity and regulates TNF-induced NF-kappaB
RT   signaling and cell death.";
RL   EMBO Rep. 17:1485-1497(2016).
RN   [21]
RP   INTERACTION WITH SPATA2.
RX   PubMed=27545878; DOI=10.1016/j.celrep.2016.07.086;
RA   Kupka S., De Miguel D., Draber P., Martino L., Surinova S., Rittinger K.,
RA   Walczak H.;
RT   "SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to
RT   Signaling Complexes.";
RL   Cell Rep. 16:2271-2280(2016).
RN   [22]
RP   INTERACTION WITH CYLD.
RX   PubMed=26997266; DOI=10.1016/j.celrep.2016.02.062;
RA   Hrdinka M., Fiil B.K., Zucca M., Leske D., Bagola K., Yabal M.,
RA   Elliott P.R., Damgaard R.B., Komander D., Jost P.J., Gyrd-Hansen M.;
RT   "CYLD limits Lys63- and Met1-linked ubiquitin at receptor complexes to
RT   regulate innate immune signaling.";
RL   Cell Rep. 14:2846-2858(2016).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH CARD11.
RX   PubMed=27777308; DOI=10.1074/jbc.m116.754028;
RA   Yang Y.K., Yang C., Chan W., Wang Z., Deibel K.E., Pomerantz J.L.;
RT   "Molecular determinants of scaffold-induced linear ubiquitinylation of B
RT   Cell Lymphoma/Leukemia 10 (Bcl10) during T cell receptor and oncogenic
RT   caspase recruitment domain-containing protein 11 (CARD11) signaling.";
RL   J. Biol. Chem. 291:25921-25936(2016).
RN   [24]
RP   INTERACTION WITH S.FLEXNERI IPAH1.4 AND IPAH2.5 (MICROBIAL INFECTION),
RP   UBIQUITINATION AT LYS-735; LYS-783 AND LYS-875 (MICROBIAL INFECTION), AND
RP   MUTAGENESIS OF LYS-735; LYS-783 AND LYS-875.
RX   PubMed=27572974; DOI=10.1038/nmicrobiol.2016.84;
RA   de Jong M.F., Liu Z., Chen D., Alto N.M.;
RT   "Shigella flexneri suppresses NF-kappaB activation by inhibiting linear
RT   ubiquitin chain ligation.";
RL   Nat. Microbiol. 1:16084-16084(2016).
RN   [25]
RP   FUNCTION, CATALYTIC ACTIVITY, IDENTIFICATION IN THE LUBAC COMPLEX, PATHWAY,
RP   UBIQUITINATION (MICROBIAL INFECTION), AND MUTAGENESIS OF THR-360; CYS-885;
RP   ARG-935 AND ASP-983.
RX   PubMed=28481331; DOI=10.1038/nmicrobiol.2017.63;
RA   Noad J., von der Malsburg A., Pathe C., Michel M.A., Komander D.,
RA   Randow F.;
RT   "LUBAC-synthesized linear ubiquitin chains restrict cytosol-invading
RT   bacteria by activating autophagy and NF-kappaB.";
RL   Nat. Microbiol. 2:17063-17063(2017).
RN   [26]
RP   FUNCTION, INTERACTION WITH SPATA2, PROTEOLYTIC CLEAVAGE, AND MUTAGENESIS OF
RP   ASP-390.
RX   PubMed=28189684; DOI=10.1016/j.bbrc.2017.02.040;
RA   Goto E., Tokunaga F.;
RT   "Decreased linear ubiquitination of NEMO and FADD on apoptosis with
RT   caspase-mediated cleavage of HOIP.";
RL   Biochem. Biophys. Res. Commun. 485:152-159(2017).
RN   [27]
RP   FUNCTION.
RX   PubMed=34012115; DOI=10.1038/s41586-021-03566-4;
RA   Otten E.G., Werner E., Crespillo-Casado A., Boyle K.B., Dharamdasani V.,
RA   Pathe C., Santhanam B., Randow F.;
RT   "Ubiquitylation of lipopolysaccharide by RNF213 during bacterial
RT   infection.";
RL   Nature 594:111-116(2021).
RN   [28]
RP   STRUCTURE BY NMR OF 779-851.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the IBR domain of the RING finger protein 31.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-184 IN COMPLEX WITH OTULIN,
RP   UBIQUITINATION, DOMAIN, INTERACTION WITH OTULIN, IDENTIFICATION IN THE
RP   LUBAC COMPLEX, AND MUTAGENESIS OF TYR-82; ASN-85; LYS-99; ASN-101; ASN-102
RP   AND VAL-104.
RX   PubMed=24726323; DOI=10.1016/j.molcel.2014.03.018;
RA   Elliott P.R., Nielsen S.V., Marco-Casanova P., Fiil B.K., Keusekotten K.,
RA   Mailand N., Freund S.M., Gyrd-Hansen M., Komander D.;
RT   "Molecular basis and regulation of OTULIN-LUBAC interaction.";
RL   Mol. Cell 54:335-348(2014).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 1-179 IN COMPLEX WITH OTULIN, AND
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1-179 IN COMPLEX WITH VCP.
RX   PubMed=24726327; DOI=10.1016/j.molcel.2014.03.016;
RA   Schaeffer V., Akutsu M., Olma M.H., Gomes L.C., Kawasaki M., Dikic I.;
RT   "Binding of OTULIN to the PUB domain of HOIP controls NF-kappaB
RT   signaling.";
RL   Mol. Cell 54:349-361(2014).
RN   [31] {ECO:0007744|PDB:5LJN}
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 5-176 IN COMPLEX WITH SPATA2, AND
RP   INTERACTION WITH SPATA2.
RX   PubMed=27591049; DOI=10.1016/j.molcel.2016.08.001;
RA   Elliott P.R., Leske D., Hrdinka M., Bagola K., Fiil B.K., McLaughlin S.H.,
RA   Wagstaff J., Volkmar N., Christianson J.C., Kessler B.M., Freund S.M.,
RA   Komander D., Gyrd-Hansen M.;
RT   "SPATA2 links CYLD to LUBAC, activates CYLD, and controls LUBAC
RT   signaling.";
RL   Mol. Cell 63:990-1005(2016).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase component of the LUBAC complex
CC       which conjugates linear ('Met-1'-linked) polyubiquitin chains to
CC       substrates and plays a key role in NF-kappa-B activation and regulation
CC       of inflammation (PubMed:17006537, PubMed:19136968, PubMed:20005846,
CC       PubMed:21455173, PubMed:21455180, PubMed:21455181, PubMed:22863777,
CC       PubMed:28481331, PubMed:28189684). LUBAC conjugates linear
CC       polyubiquitin to IKBKG and RIPK1 and is involved in activation of the
CC       canonical NF-kappa-B and the JNK signaling pathways (PubMed:17006537,
CC       PubMed:19136968, PubMed:20005846, PubMed:21455173, PubMed:21455180,
CC       PubMed:21455181, PubMed:22863777, PubMed:28189684). Linear
CC       ubiquitination mediated by the LUBAC complex interferes with TNF-
CC       induced cell death and thereby prevents inflammation (PubMed:21455173,
CC       PubMed:28189684). LUBAC is recruited to the TNF-R1 signaling complex
CC       (TNF-RSC) following polyubiquitination of TNF-RSC components by BIRC2
CC       and/or BIRC3 and to conjugate linear polyubiquitin to IKBKG and
CC       possibly other components contributing to the stability of the complex
CC       (PubMed:20005846, PubMed:27458237). The LUBAC complex is also involved
CC       in innate immunity by conjugating linear polyubiquitin chains at the
CC       surface of bacteria invading the cytosol to form the ubiquitin coat
CC       surrounding bacteria (PubMed:28481331, PubMed:34012115). LUBAC is not
CC       able to initiate formation of the bacterial ubiquitin coat, and can
CC       only promote formation of linear polyubiquitins on pre-existing
CC       ubiquitin (PubMed:28481331). Recruited to the surface of bacteria by
CC       RNF213, which initiates the bacterial ubiquitin coat (PubMed:34012115).
CC       The bacterial ubiquitin coat acts as an 'eat-me' signal for xenophagy
CC       and promotes NF-kappa-B activation (PubMed:28481331, PubMed:34012115).
CC       Together with OTULIN, the LUBAC complex regulates the canonical Wnt
CC       signaling during angiogenesis (PubMed:23708998). RNF31 is required for
CC       linear ubiquitination of BCL10, thereby promoting TCR-induced NF-kappa-
CC       B activation (PubMed:27777308). Binds polyubiquitin of different
CC       linkage types (PubMed:23708998). {ECO:0000269|PubMed:17006537,
CC       ECO:0000269|PubMed:19136968, ECO:0000269|PubMed:20005846,
CC       ECO:0000269|PubMed:21455173, ECO:0000269|PubMed:21455180,
CC       ECO:0000269|PubMed:21455181, ECO:0000269|PubMed:22863777,
CC       ECO:0000269|PubMed:23708998, ECO:0000269|PubMed:27458237,
CC       ECO:0000269|PubMed:27777308, ECO:0000269|PubMed:28189684,
CC       ECO:0000269|PubMed:28481331, ECO:0000269|PubMed:34012115}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[E2 ubiquitin-conjugating enzyme]-S-ubiquitinyl-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + [acceptor protein]-N(6)-ubiquitinyl-L-lysine.;
CC         EC=2.3.2.31; Evidence={ECO:0000269|PubMed:17006537,
CC         ECO:0000269|PubMed:19136968, ECO:0000269|PubMed:20005846,
CC         ECO:0000269|PubMed:28481331};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:17006537, ECO:0000269|PubMed:19136968,
CC       ECO:0000269|PubMed:20005846, ECO:0000269|PubMed:28481331}.
CC   -!- SUBUNIT: Component of the LUBAC complex (linear ubiquitin chain
CC       assembly complex) which consists of SHARPIN, RBCK1 and RNF31
CC       (PubMed:17006537, PubMed:21455173, PubMed:21455180, PubMed:21455181,
CC       PubMed:28481331). LUBAC has a MW of approximately 600 kDa suggesting a
CC       heteromultimeric assembly of its subunits (PubMed:17006537,
CC       PubMed:21455173, PubMed:21455180, PubMed:21455181). Associates with the
CC       TNF-R1 signaling complex (TNF-RSC) in a stimulation-dependent manner
CC       (PubMed:20005846). Interacts (via the PUB domain) with OTULIN (via the
CC       PIM motif); the interaction is direct (PubMed:23708998,
CC       PubMed:24726323, PubMed:24726327). Interacts (via the PUB domain) with
CC       VCP (via the PIM motif) (PubMed:24726327). Interacts (via the PUB
CC       domain) with SPATA2 (via the PIM motif); interaction is direct and
CC       bridges RNF31 and CYLD (PubMed:27458237, PubMed:27545878,
CC       PubMed:28189684, PubMed:27591049). Interacts with CYLD; the interaction
CC       is indirect and is mediated via SPATA2 (PubMed:27458237,
CC       PubMed:27545878, PubMed:26997266). Interacts with MUSK (By similarity).
CC       Interacts with CARD11, promoting linear ubiquitination of BCL10
CC       (PubMed:27777308). {ECO:0000250|UniProtKB:Q924T7,
CC       ECO:0000269|PubMed:17006537, ECO:0000269|PubMed:20005846,
CC       ECO:0000269|PubMed:21455173, ECO:0000269|PubMed:21455180,
CC       ECO:0000269|PubMed:21455181, ECO:0000269|PubMed:22430200,
CC       ECO:0000269|PubMed:23708998, ECO:0000269|PubMed:24726323,
CC       ECO:0000269|PubMed:24726327, ECO:0000269|PubMed:26997266,
CC       ECO:0000269|PubMed:27458237, ECO:0000269|PubMed:27545878,
CC       ECO:0000269|PubMed:27591049, ECO:0000269|PubMed:27777308,
CC       ECO:0000269|PubMed:28189684, ECO:0000269|PubMed:28481331}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with S.flexneri E3 ubiquitin-
CC       protein ligases IpaH1.4 and IpaH2.5, leading to its ubiquitination.
CC       {ECO:0000269|PubMed:27572974}.
CC   -!- INTERACTION:
CC       Q96EP0; P54253: ATXN1; NbExp=4; IntAct=EBI-948111, EBI-930964;
CC       Q96EP0; P54252: ATXN3; NbExp=3; IntAct=EBI-948111, EBI-946046;
CC       Q96EP0; O14645: DNALI1; NbExp=3; IntAct=EBI-948111, EBI-395638;
CC       Q96EP0; Q9UMF0: ICAM5; NbExp=3; IntAct=EBI-948111, EBI-6398041;
CC       Q96EP0; Q9Y6K9: IKBKG; NbExp=10; IntAct=EBI-948111, EBI-81279;
CC       Q96EP0; O14901: KLF11; NbExp=3; IntAct=EBI-948111, EBI-948266;
CC       Q96EP0; Q9BVL2: NUP58; NbExp=3; IntAct=EBI-948111, EBI-2811583;
CC       Q96EP0; Q9BYM8: RBCK1; NbExp=48; IntAct=EBI-948111, EBI-2340624;
CC       Q96EP0; Q96EP0: RNF31; NbExp=3; IntAct=EBI-948111, EBI-948111;
CC       Q96EP0; Q9H0F6: SHARPIN; NbExp=32; IntAct=EBI-948111, EBI-3942966;
CC       Q96EP0; P84022: SMAD3; NbExp=2; IntAct=EBI-948111, EBI-347161;
CC       Q96EP0; P62837: UBE2D2; NbExp=3; IntAct=EBI-948111, EBI-347677;
CC       Q96EP0; Q9QYP6: Azi2; Xeno; NbExp=2; IntAct=EBI-948111, EBI-6115874;
CC       Q96EP0; Q4VA12: Traf1; Xeno; NbExp=2; IntAct=EBI-948111, EBI-6116765;
CC       Q96EP0-3; Q8N4L8: CCDC24; NbExp=3; IntAct=EBI-10225152, EBI-1104933;
CC       Q96EP0-3; Q9BYQ4: KRTAP9-2; NbExp=3; IntAct=EBI-10225152, EBI-1044640;
CC       Q96EP0-3; Q5TAL4: SNRPC; NbExp=3; IntAct=EBI-10225152, EBI-10246938;
CC       Q96EP0-3; Q08117: TLE5; NbExp=3; IntAct=EBI-10225152, EBI-717810;
CC       Q96EP0-3; Q9Y5U2: TSSC4; NbExp=3; IntAct=EBI-10225152, EBI-717229;
CC       Q96EP0-3; Q6EMK4: VASN; NbExp=3; IntAct=EBI-10225152, EBI-10249550;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q924T7}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q96EP0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96EP0-2; Sequence=VSP_009647, VSP_009648;
CC       Name=3;
CC         IsoId=Q96EP0-3; Sequence=VSP_014006, VSP_014007;
CC   -!- TISSUE SPECIFICITY: Expressed in both normal and transformed breast
CC       epithelial cell lines. {ECO:0000269|PubMed:15093743}.
CC   -!- DOMAIN: The PUB domain mediates interaction with the PIM motifs of VCP
CC       and RNF31, with a strong preference for RNF31.
CC       {ECO:0000269|PubMed:24726323, ECO:0000269|PubMed:24726327}.
CC   -!- DOMAIN: The RanBP2-type zinc fingers mediate the specific interaction
CC       with ubiquitin. {ECO:0000269|PubMed:21455181}.
CC   -!- DOMAIN: The UBA domain mediates association with RBCK1/HOIL1 via
CC       interaction with its UBL domain.
CC   -!- DOMAIN: RING 1 and IBR zinc-fingers catalyze the first step transfer of
CC       ubiquitin from the E2 onto RING 2, to transiently form a HECT-like
CC       covalent thioester intermediate. {ECO:0000269|PubMed:22863777}.
CC   -!- DOMAIN: The linear ubiquitin chain determining domain (LDD) mediates
CC       the final transfer of ubiquitin from RING 2 onto the N-terminus of a
CC       target ubiquitin. {ECO:0000269|PubMed:22863777}.
CC   -!- PTM: Autoubiquitinated (PubMed:24726323). Interaction with OTULIN is
CC       required to suppress formation of 'Met-1'-linked polyubiquitin chains
CC       and prevent subsequent inactivation of the LUBAC complex
CC       (PubMed:24726323). {ECO:0000269|PubMed:24726323}.
CC   -!- PTM: Cleaved by caspase during apoptosis.
CC       {ECO:0000269|PubMed:28189684}.
CC   -!- PTM: (Microbial infection) Ubiquitinated by S.flexneri E3 ubiquitin-
CC       protein ligases IpaH1.4 and IpaH2.5, leading to its degradation by the
CC       proteasome, thereby preventing formation of the bacterial ubiquitin
CC       coat and activation of innate immunity. {ECO:0000269|PubMed:27572974,
CC       ECO:0000269|PubMed:28481331}.
CC   -!- SIMILARITY: Belongs to the RBR family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15675.1; Type=Erroneous termination; Note=Truncated C-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB15675.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAB15675.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC       Sequence=BAB70948.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY256461; AAP12522.1; -; mRNA.
DR   EMBL; AB265810; BAF35583.1; -; mRNA.
DR   EMBL; AK000973; BAA91450.1; -; mRNA.
DR   EMBL; AK027154; BAB15675.1; ALT_FRAME; mRNA.
DR   EMBL; AK055542; BAB70948.1; ALT_INIT; mRNA.
DR   EMBL; AK291247; BAF83936.1; -; mRNA.
DR   EMBL; AL136295; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471078; EAW66098.1; -; Genomic_DNA.
DR   EMBL; BC009821; AAH09821.3; -; mRNA.
DR   EMBL; BC012077; AAH12077.1; -; mRNA.
DR   EMBL; BC017376; AAH17376.3; -; mRNA.
DR   EMBL; AK074144; BAB84970.1; -; mRNA.
DR   CCDS; CCDS41931.1; -. [Q96EP0-1]
DR   CCDS; CCDS81792.1; -. [Q96EP0-3]
DR   RefSeq; NP_001297261.1; NM_001310332.1. [Q96EP0-3]
DR   RefSeq; NP_060469.4; NM_017999.4. [Q96EP0-1]
DR   PDB; 2CT7; NMR; -; A=779-851.
DR   PDB; 4DBG; X-ray; 2.71 A; B=480-636.
DR   PDB; 4JUY; X-ray; 2.40 A; A/B=1-180.
DR   PDB; 4LJO; X-ray; 1.56 A; A=853-1072.
DR   PDB; 4LJP; X-ray; 2.15 A; A=853-1072.
DR   PDB; 4LJQ; X-ray; 2.45 A; A/B/C/D=853-1072.
DR   PDB; 4OWF; X-ray; 2.00 A; G=350-379.
DR   PDB; 4OYJ; X-ray; 3.00 A; A/B/C/D/E/F/G/H/I/J/K/L/M=1-184.
DR   PDB; 4OYK; X-ray; 2.00 A; A/B=3-179.
DR   PDB; 4P09; X-ray; 1.70 A; A=1-179.
DR   PDB; 4P0A; X-ray; 2.30 A; A/C=1-179.
DR   PDB; 4P0B; X-ray; 2.70 A; A/C=1-179.
DR   PDB; 5EDV; X-ray; 3.48 A; A/B=696-1072.
DR   PDB; 5LJN; X-ray; 2.70 A; A/B=5-176.
DR   PDB; 5X0W; X-ray; 3.00 A; A/C/E/G=480-639.
DR   PDB; 6GZY; X-ray; 2.15 A; A/B=853-1072.
DR   PDB; 6KC5; X-ray; 1.54 A; B=853-1072.
DR   PDB; 6KC6; X-ray; 2.12 A; A/C/E/G/I/K=853-1072.
DR   PDB; 6SC5; X-ray; 2.10 A; A=697-1072.
DR   PDB; 6SC6; X-ray; 2.25 A; A=697-1072.
DR   PDB; 6SC7; X-ray; 2.56 A; A=697-1072.
DR   PDB; 6SC8; X-ray; 2.11 A; A=697-1072.
DR   PDB; 6SC9; X-ray; 2.47 A; A=697-1072.
DR   PDB; 7TV4; X-ray; 4.20 A; K=350-379.
DR   PDB; 7UY2; X-ray; 2.51 A; A/B=1-179.
DR   PDB; 7UYJ; X-ray; 2.32 A; A/B=1-179.
DR   PDB; 7UYK; X-ray; 2.70 A; A/B=480-639.
DR   PDB; 7V8F; X-ray; 1.66 A; B=697-793.
DR   PDB; 7V8G; X-ray; 2.75 A; C/D=697-793.
DR   PDBsum; 2CT7; -.
DR   PDBsum; 4DBG; -.
DR   PDBsum; 4JUY; -.
DR   PDBsum; 4LJO; -.
DR   PDBsum; 4LJP; -.
DR   PDBsum; 4LJQ; -.
DR   PDBsum; 4OWF; -.
DR   PDBsum; 4OYJ; -.
DR   PDBsum; 4OYK; -.
DR   PDBsum; 4P09; -.
DR   PDBsum; 4P0A; -.
DR   PDBsum; 4P0B; -.
DR   PDBsum; 5EDV; -.
DR   PDBsum; 5LJN; -.
DR   PDBsum; 5X0W; -.
DR   PDBsum; 6GZY; -.
DR   PDBsum; 6KC5; -.
DR   PDBsum; 6KC6; -.
DR   PDBsum; 6SC5; -.
DR   PDBsum; 6SC6; -.
DR   PDBsum; 6SC7; -.
DR   PDBsum; 6SC8; -.
DR   PDBsum; 6SC9; -.
DR   PDBsum; 7TV4; -.
DR   PDBsum; 7UY2; -.
DR   PDBsum; 7UYJ; -.
DR   PDBsum; 7UYK; -.
DR   PDBsum; 7V8F; -.
DR   PDBsum; 7V8G; -.
DR   AlphaFoldDB; Q96EP0; -.
DR   BMRB; Q96EP0; -.
DR   SMR; Q96EP0; -.
DR   BioGRID; 120389; 426.
DR   ComplexPortal; CPX-1877; LUBAC ubiquitin ligase complex.
DR   CORUM; Q96EP0; -.
DR   DIP; DIP-44034N; -.
DR   IntAct; Q96EP0; 70.
DR   MINT; Q96EP0; -.
DR   STRING; 9606.ENSP00000315112; -.
DR   BindingDB; Q96EP0; -.
DR   ChEMBL; CHEMBL4296109; -.
DR   iPTMnet; Q96EP0; -.
DR   MetOSite; Q96EP0; -.
DR   PhosphoSitePlus; Q96EP0; -.
DR   BioMuta; RNF31; -.
DR   DMDM; 45477216; -.
DR   EPD; Q96EP0; -.
DR   jPOST; Q96EP0; -.
DR   MassIVE; Q96EP0; -.
DR   MaxQB; Q96EP0; -.
DR   PaxDb; Q96EP0; -.
DR   PeptideAtlas; Q96EP0; -.
DR   ProteomicsDB; 76429; -. [Q96EP0-1]
DR   ProteomicsDB; 76430; -. [Q96EP0-2]
DR   ProteomicsDB; 76431; -. [Q96EP0-3]
DR   ABCD; Q96EP0; 10 sequenced antibodies.
DR   Antibodypedia; 22671; 276 antibodies from 36 providers.
DR   DNASU; 55072; -.
DR   Ensembl; ENST00000324103.11; ENSP00000315112.6; ENSG00000092098.18. [Q96EP0-1]
DR   Ensembl; ENST00000559275.5; ENSP00000453574.1; ENSG00000092098.18. [Q96EP0-3]
DR   Ensembl; ENST00000642631.1; ENSP00000494011.1; ENSG00000285152.2. [Q96EP0-3]
DR   Ensembl; ENST00000647495.2; ENSP00000496609.1; ENSG00000285152.2. [Q96EP0-1]
DR   GeneID; 55072; -.
DR   KEGG; hsa:55072; -.
DR   MANE-Select; ENST00000324103.11; ENSP00000315112.6; NM_017999.5; NP_060469.4.
DR   UCSC; uc001wml.2; human. [Q96EP0-1]
DR   AGR; HGNC:16031; -.
DR   CTD; 55072; -.
DR   DisGeNET; 55072; -.
DR   GeneCards; RNF31; -.
DR   HGNC; HGNC:16031; RNF31.
DR   HPA; ENSG00000092098; Low tissue specificity.
DR   MalaCards; RNF31; -.
DR   MIM; 612487; gene.
DR   neXtProt; NX_Q96EP0; -.
DR   OpenTargets; ENSG00000092098; -.
DR   OpenTargets; ENSG00000259529; -.
DR   Orphanet; 329173; Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis.
DR   PharmGKB; PA134906471; -.
DR   VEuPathDB; HostDB:ENSG00000092098; -.
DR   eggNOG; KOG1812; Eukaryota.
DR   GeneTree; ENSGT00530000064112; -.
DR   InParanoid; Q96EP0; -.
DR   OMA; YNTFYAK; -.
DR   OrthoDB; 2909614at2759; -.
DR   PhylomeDB; Q96EP0; -.
DR   TreeFam; TF350529; -.
DR   BRENDA; 2.3.2.31; 2681.
DR   PathwayCommons; Q96EP0; -.
DR   Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   SignaLink; Q96EP0; -.
DR   SIGNOR; Q96EP0; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 55072; 92 hits in 1199 CRISPR screens.
DR   ChiTaRS; RNF31; human.
DR   EvolutionaryTrace; Q96EP0; -.
DR   GeneWiki; RNF31; -.
DR   GenomeRNAi; 55072; -.
DR   Pharos; Q96EP0; Tbio.
DR   PRO; PR:Q96EP0; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q96EP0; protein.
DR   Bgee; ENSG00000092098; Expressed in spleen and 97 other tissues.
DR   ExpressionAtlas; Q96EP0; baseline and differential.
DR   Genevisible; Q96EP0; HS.
DR   GO; GO:0035631; C:CD40 receptor complex; ISS:BHF-UCL.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0071797; C:LUBAC complex; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0036435; F:K48-linked polyubiquitin modification-dependent protein binding; IBA:GO_Central.
DR   GO; GO:0070530; F:K63-linked polyubiquitin modification-dependent protein binding; IBA:GO_Central.
DR   GO; GO:1990450; F:linear polyubiquitin binding; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0023035; P:CD40 signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0042742; P:defense response to bacterium; IDA:UniProtKB.
DR   GO; GO:0060546; P:negative regulation of necroptotic process; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; HMP:ParkinsonsUK-UCL.
DR   GO; GO:1904417; P:positive regulation of xenophagy; IDA:UniProtKB.
DR   GO; GO:0097039; P:protein linear polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IDA:UniProtKB.
DR   CDD; cd19815; Bbox1_HOIP; 1.
DR   CDD; cd20337; BRcat_RBR_HOIP; 1.
DR   CDD; cd16631; mRING-HC-C4C4_RBR_HOIP; 1.
DR   CDD; cd10464; PUB_RNF31; 1.
DR   CDD; cd20351; Rcat_RBR_HOIP; 1.
DR   CDD; cd14325; UBA_RNF31; 1.
DR   Gene3D; 1.20.120.1750; -; 1.
DR   Gene3D; 1.20.58.2190; -; 1.
DR   Gene3D; 6.10.140.1100; -; 1.
DR   Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1.
DR   Gene3D; 4.10.1060.10; Zinc finger, RanBP2-type; 1.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   IDEAL; IID00576; -.
DR   InterPro; IPR047543; Bbox1_RNF31-like.
DR   InterPro; IPR047540; BRcat_RBR_RNF31-like.
DR   InterPro; IPR002867; IBR_dom.
DR   InterPro; IPR036339; PUB-like_dom_sf.
DR   InterPro; IPR018997; PUB_domain.
DR   InterPro; IPR047542; Rcat_RBR_RNF31-like.
DR   InterPro; IPR026254; RNF31-like.
DR   InterPro; IPR032065; RNF31-UBA.
DR   InterPro; IPR041031; RNF31_C.
DR   InterPro; IPR040641; RNF31_PUB.
DR   InterPro; IPR047541; RNF31_RBR_mRING-HC-like.
DR   InterPro; IPR044066; TRIAD_supradom.
DR   InterPro; IPR015940; UBA.
DR   InterPro; IPR047539; UBA_RNF31.
DR   InterPro; IPR001876; Znf_RanBP2.
DR   InterPro; IPR036443; Znf_RanBP2_sf.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR16004:SF2; E3 UBIQUITIN-PROTEIN LIGASE RNF31; 1.
DR   PANTHER; PTHR16004; RING FINGER PROTEIN 31-RELATED; 1.
DR   Pfam; PF18091; E3_UbLigase_RBR; 1.
DR   Pfam; PF16678; HOIP-UBA; 1.
DR   Pfam; PF01485; IBR; 1.
DR   Pfam; PF09409; PUB; 1.
DR   Pfam; PF18486; PUB_1; 1.
DR   SMART; SM00647; IBR; 2.
DR   SMART; SM00547; ZnF_RBZ; 3.
DR   SUPFAM; SSF143503; PUG domain-like; 1.
DR   SUPFAM; SSF90209; Ran binding protein zinc finger-like; 1.
DR   SUPFAM; SSF57850; RING/U-box; 3.
DR   PROSITE; PS51873; TRIAD; 1.
DR   PROSITE; PS50030; UBA; 1.
DR   PROSITE; PS01358; ZF_RANBP2_1; 3.
DR   PROSITE; PS50199; ZF_RANBP2_2; 2.
DR   PROSITE; PS00518; ZF_RING_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Isopeptide bond;
KW   Metal-binding; Phosphoprotein; Reference proteome; Repeat; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..1072
FT                   /note="E3 ubiquitin-protein ligase RNF31"
FT                   /id="PRO_0000056069"
FT   DOMAIN          71..142
FT                   /note="PUB"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          564..615
FT                   /note="UBA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00212"
FT   ZN_FING         299..329
FT                   /note="RanBP2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00322"
FT   ZN_FING         350..379
FT                   /note="RanBP2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00322"
FT   ZN_FING         409..438
FT                   /note="RanBP2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00322"
FT   ZN_FING         699..749
FT                   /note="RING-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   ZN_FING         779..841
FT                   /note="IBR-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   ZN_FING         871..901
FT                   /note="RING-type 2; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   REGION          1..485
FT                   /note="Polyubiquitin-binding"
FT   REGION          263..290
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          443..484
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          563..616
FT                   /note="Interaction with RBCK1"
FT   REGION          695..929
FT                   /note="TRIAD supradomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   REGION          910..1072
FT                   /note="LDD domain"
FT   COMPBIAS        452..466
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        885
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         699
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         702
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         722
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         725
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         799
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         802
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         817
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         820
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         825
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         828
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         836
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         841
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         871
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         874
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         890
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         893
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         898
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         901
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         916
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   BINDING         925
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01221"
FT   SITE            390..391
FT                   /note="Cleavage; by caspase"
FT                   /evidence="ECO:0000269|PubMed:28189684"
FT   MOD_RES         383
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         466
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   CROSSLNK        735
FT                   /note="(Microbial infection) Glycyl lysine isopeptide (Lys-
FT                   Gly) (interchain with G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:27572974"
FT   CROSSLNK        783
FT                   /note="(Microbial infection) Glycyl lysine isopeptide (Lys-
FT                   Gly) (interchain with G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:27572974"
FT   CROSSLNK        875
FT                   /note="(Microbial infection) Glycyl lysine isopeptide (Lys-
FT                   Gly) (interchain with G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:27572974"
FT   VAR_SEQ         1..151
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15093743"
FT                   /id="VSP_014006"
FT   VAR_SEQ         73..630
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_009647"
FT   VAR_SEQ         152..164
FT                   /note="EVLLLRTELSLLL -> MDLCTRAGEPSLT (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15093743"
FT                   /id="VSP_014007"
FT   VAR_SEQ         833..841
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_009648"
FT   VARIANT         1061
FT                   /note="V -> I (in dbSNP:rs2277484)"
FT                   /evidence="ECO:0000269|PubMed:14702039"
FT                   /id="VAR_052102"
FT   MUTAGEN         82
FT                   /note="Y->A: Abolished interaction with OTULIN."
FT                   /evidence="ECO:0000269|PubMed:24726323"
FT   MUTAGEN         82
FT                   /note="Y->F: Reduced interaction with OTULIN."
FT                   /evidence="ECO:0000269|PubMed:24726323"
FT   MUTAGEN         85
FT                   /note="N->A: Reduced interaction with OTULIN."
FT                   /evidence="ECO:0000269|PubMed:24726323"
FT   MUTAGEN         99
FT                   /note="K->E: Reduced interaction with OTULIN."
FT                   /evidence="ECO:0000269|PubMed:24726323"
FT   MUTAGEN         101
FT                   /note="N->R: Does not affect interaction with OTULIN."
FT                   /evidence="ECO:0000269|PubMed:24726323"
FT   MUTAGEN         102
FT                   /note="N->A: Abolished interaction with SPATA2."
FT                   /evidence="ECO:0000269|PubMed:27458237"
FT   MUTAGEN         102
FT                   /note="N->D: Abolished interaction with OTULIN."
FT                   /evidence="ECO:0000269|PubMed:24726323"
FT   MUTAGEN         104
FT                   /note="V->A: Reduced interaction with OTULIN."
FT                   /evidence="ECO:0000269|PubMed:24726323"
FT   MUTAGEN         360
FT                   /note="T->A: Decreased ubiquitin-binding and ability to
FT                   promote formation of the bacterial ubiquitin coat."
FT                   /evidence="ECO:0000269|PubMed:28481331"
FT   MUTAGEN         390
FT                   /note="D->A: Abolishes cleavage by caspase."
FT                   /evidence="ECO:0000269|PubMed:28189684"
FT   MUTAGEN         699
FT                   /note="C->S: Abolishes polyubiquitination activity of
FT                   LUBAC; when associated with S-702."
FT                   /evidence="ECO:0000269|PubMed:17006537,
FT                   ECO:0000269|PubMed:21455181"
FT   MUTAGEN         702
FT                   /note="C->S: Abolishes polyubiquitination activity of
FT                   LUBAC; when associated with S-699."
FT                   /evidence="ECO:0000269|PubMed:17006537,
FT                   ECO:0000269|PubMed:21455181"
FT   MUTAGEN         735
FT                   /note="K->R: Reduced ubiquitination; when associated with
FT                   R-783 and R-875."
FT                   /evidence="ECO:0000269|PubMed:27572974"
FT   MUTAGEN         783
FT                   /note="K->R: Reduced ubiquitination; when associated with
FT                   R-735 and R-875."
FT                   /evidence="ECO:0000269|PubMed:27572974"
FT   MUTAGEN         871
FT                   /note="C->S: Abolishes polyubiquitination activity of
FT                   LUBAC; when associated with S-874."
FT                   /evidence="ECO:0000269|PubMed:17006537,
FT                   ECO:0000269|PubMed:21455181"
FT   MUTAGEN         874
FT                   /note="C->S: Abolishes polyubiquitination activity of
FT                   LUBAC; when associated with S-871."
FT                   /evidence="ECO:0000269|PubMed:17006537,
FT                   ECO:0000269|PubMed:21455181"
FT   MUTAGEN         875
FT                   /note="K->R: Reduced ubiquitination; when associated with
FT                   R-735 and R-783."
FT                   /evidence="ECO:0000269|PubMed:27572974"
FT   MUTAGEN         885
FT                   /note="C->A: Abolished E3 ubiquitin-protein ligase activity
FT                   and ability to promote formation of the bacterial ubiquitin
FT                   coat; when associated with A-935 and A-983."
FT                   /evidence="ECO:0000269|PubMed:28481331"
FT   MUTAGEN         935
FT                   /note="R->A: Abolished E3 ubiquitin-protein ligase activity
FT                   and ability to promote formation of the bacterial ubiquitin
FT                   coat; when associated with A-885 and A-983."
FT                   /evidence="ECO:0000269|PubMed:28481331"
FT   MUTAGEN         983
FT                   /note="D->A: Abolished E3 ubiquitin-protein ligase activity
FT                   and ability to promote formation of the bacterial ubiquitin
FT                   coat; when associated with A-885 and A-935."
FT                   /evidence="ECO:0000269|PubMed:28481331"
FT   CONFLICT        529
FT                   /note="P -> S (in Ref. 1; AAP12522)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        800
FT                   /note="A -> V (in Ref. 3; BAA91450)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        925
FT                   /note="H -> R (in Ref. 3; BAB15675)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1005
FT                   /note="Y -> N (in Ref. 3; BAB15675)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1018
FT                   /note="A -> S (in Ref. 3; BAB15675)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1021
FT                   /note="Y -> D (in Ref. 3; BAB15675)"
FT                   /evidence="ECO:0000305"
FT   HELIX           4..23
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   HELIX           31..38
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   HELIX           44..47
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   STRAND          49..51
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   HELIX           53..58
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   HELIX           65..86
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   STRAND          88..90
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   TURN            93..96
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   STRAND          97..102
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   HELIX           103..107
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   HELIX           109..111
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   HELIX           115..122
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   STRAND          126..128
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   STRAND          131..133
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   HELIX           143..164
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   HELIX           171..177
FT                   /evidence="ECO:0007829|PDB:4P09"
FT   TURN            357..359
FT                   /evidence="ECO:0007829|PDB:4OWF"
FT   TURN            371..373
FT                   /evidence="ECO:0007829|PDB:4OWF"
FT   HELIX           483..493
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   HELIX           505..515
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   HELIX           521..527
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   HELIX           531..542
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   HELIX           544..546
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   HELIX           551..560
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   TURN            561..563
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   HELIX           565..585
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   HELIX           590..592
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   HELIX           594..600
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   TURN            601..603
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   HELIX           605..616
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   HELIX           618..625
FT                   /evidence="ECO:0007829|PDB:4DBG"
FT   TURN            700..702
FT                   /evidence="ECO:0007829|PDB:7V8F"
FT   STRAND          705..707
FT                   /evidence="ECO:0007829|PDB:7V8F"
FT   HELIX           708..710
FT                   /evidence="ECO:0007829|PDB:7V8F"
FT   STRAND          711..713
FT                   /evidence="ECO:0007829|PDB:7V8F"
FT   TURN            715..717
FT                   /evidence="ECO:0007829|PDB:6SC5"
FT   HELIX           723..736
FT                   /evidence="ECO:0007829|PDB:7V8F"
FT   HELIX           739..741
FT                   /evidence="ECO:0007829|PDB:7V8F"
FT   TURN            745..747
FT                   /evidence="ECO:0007829|PDB:7V8F"
FT   HELIX           755..757
FT                   /evidence="ECO:0007829|PDB:7V8F"
FT   HELIX           758..772
FT                   /evidence="ECO:0007829|PDB:7V8F"
FT   HELIX           775..787
FT                   /evidence="ECO:0007829|PDB:7V8F"
FT   STRAND          796..798
FT                   /evidence="ECO:0007829|PDB:6SC5"
FT   TURN            800..802
FT                   /evidence="ECO:0007829|PDB:6SC5"
FT   STRAND          805..807
FT                   /evidence="ECO:0007829|PDB:6SC5"
FT   STRAND          813..816
FT                   /evidence="ECO:0007829|PDB:6SC5"
FT   TURN            818..820
FT                   /evidence="ECO:0007829|PDB:6SC5"
FT   STRAND          823..825
FT                   /evidence="ECO:0007829|PDB:6SC5"
FT   TURN            826..828
FT                   /evidence="ECO:0007829|PDB:6SC5"
FT   HELIX           834..836
FT                   /evidence="ECO:0007829|PDB:6SC5"
FT   HELIX           841..849
FT                   /evidence="ECO:0007829|PDB:6SC5"
FT   HELIX           853..858
FT                   /evidence="ECO:0007829|PDB:6SC5"
FT   HELIX           859..864
FT                   /evidence="ECO:0007829|PDB:4LJO"
FT   STRAND          868..870
FT                   /evidence="ECO:0007829|PDB:4LJO"
FT   TURN            872..874
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   STRAND          877..879
FT                   /evidence="ECO:0007829|PDB:4LJO"
FT   STRAND          887..889
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   TURN            891..893
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   STRAND          896..898
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   TURN            899..901
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   STRAND          904..906
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   TURN            908..910
FT                   /evidence="ECO:0007829|PDB:6SC8"
FT   TURN            917..920
FT                   /evidence="ECO:0007829|PDB:4LJO"
FT   STRAND          921..924
FT                   /evidence="ECO:0007829|PDB:4LJO"
FT   STRAND          928..930
FT                   /evidence="ECO:0007829|PDB:5EDV"
FT   HELIX           931..934
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   HELIX           939..948
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   STRAND          965..968
FT                   /evidence="ECO:0007829|PDB:4LJP"
FT   STRAND          972..977
FT                   /evidence="ECO:0007829|PDB:4LJO"
FT   STRAND          980..985
FT                   /evidence="ECO:0007829|PDB:4LJO"
FT   TURN            992..996
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   HELIX           999..1012
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   HELIX           1017..1020
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   HELIX           1023..1034
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   HELIX           1046..1060
FT                   /evidence="ECO:0007829|PDB:6KC5"
FT   STRAND          1065..1067
FT                   /evidence="ECO:0007829|PDB:6KC5"
SQ   SEQUENCE   1072 AA;  119652 MW;  CFAD183A14F764BA CRC64;
     MPGEEEERAF LVAREELASA LRRDSGQAFS LEQLRPLLAS SLPLAARYLQ LDAARLVRCN
     AHGEPRNYLN TLSTALNILE KYGRNLLSPQ RPRYWRGVKF NNPVFRSTVD AVQGGRDVLR
     LYGYTEEQPD GLSFPEGQEE PDEHQVATVT LEVLLLRTEL SLLLQNTHPR QQALEQLLED
     KVEDDMLQLS EFDPLLREIA PGPLTTPSVP GSTPGPCFLC GSAPGTLHCP SCKQALCPAC
     DHLFHGHPSR AHHLRQTLPG VLQGTHLSPS LPASAQPRPQ STSLLALGDS SLSSPNPASA
     HLPWHCAACA MLNEPWAVLC VACDRPRGCK GLGLGTEGPQ GTGGLEPDLA RGRWACQSCT
     FENEAAAVLC SICERPRLAQ PPSLVVDSRD AGICLQPLQQ GDALLASAQS QVWYCIHCTF
     CNSSPGWVCV MCNRTSSPIP AQHAPRPYAS SLEKGPPKPG PPRRLSAPLP SSCGDPEKQR
     QDKMREEGLQ LVSMIREGEA AGACPEEIFS ALQYSGTEVP LQWLRSELPY VLEMVAELAG
     QQDPGLGAFS CQEARRAWLD RHGNLDEAVE ECVRTRRRKV QELQSLGFGP EEGSLQALFQ
     HGGDVSRALT ELQRQRLEPF RQRLWDSGPE PTPSWDGPDK QSLVRRLLAV YALPSWGRAE
     LALSLLQETP RNYELGDVVE AVRHSQDRAF LRRLLAQECA VCGWALPHNR MQALTSCECT
     ICPDCFRQHF TIALKEKHIT DMVCPACGRP DLTDDTQLLS YFSTLDIQLR ESLEPDAYAL
     FHKKLTEGVL MRDPKFLWCA QCSFGFIYER EQLEATCPQC HQTFCVRCKR QWEEQHRGRS
     CEDFQNWKRM NDPEYQAQGL AMYLQENGID CPKCKFSYAL ARGGCMHFHC TQCRHQFCSG
     CYNAFYAKNK CPEPNCRVKK SLHGHHPRDC LFYLRDWTAL RLQKLLQDNN VMFNTEPPAG
     ARAVPGGGCR VIEQKEVPNG LRDEACGKET PAGYAGLCQA HYKEYLVSLI NAHSLDPATL
     YEVEELETAT ERYLHVRPQP LAGEDPPAYQ ARLLQKLTEE VPLGQSIPRR RK
//
